Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 10/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020881 | 0.93 | NPY4R (0.49) | NPY1RNPY2RNPY4RBACE1BACE2 | |
| SCHEMBL31510665 | 0.93 | BACE1 (0.52) | BACE1BACE2 | |
| SCHEMBL31513110 | 0.92 | NPY1R (0.52) | NPY1RNPY2RNPY4RBACE1BACE2 | |
| SCHEMBL29679754 | 0.90 | OPRM1 (0.54) | NPY1RNPY2RNPY4RBACE1BACE2 | |
| SCHEMBL28101251 | 0.90 | BACE1 (0.42) | BACE1BACE2 | |
| Trifluoroacetic Acid SCHEMBL31518366 | 0.89 | NPY4R (0.49) | NPY1RNPY2RNPY4RBACE1BACE2 | |
| SCHEMBL7838083 | 0.89 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL3863461 | 0.89 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL7838077 | 0.89 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL3863451 | 0.89 | BACE1 (0.46) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | PDE6C, UACA, EYA3 | NPY1R 1471/4885NPY2R 1277/4885NPY4R 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.